New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
10:07 EDTSNE, NTES, HBNC, ADSK, HAL, CF, UBSH, STM, KLAC, EQM, AMCX, PNRA, AMGN, TIF, QLGC, JPM, EBAY, SHLM, AGU, SGIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Equal Weight from Underweight at Morgan Stanley... Autodesk (ADSK) upgraded to Conviction Buy from Sell at Goldman... eBay (EBAY) upgraded to Outperform from Market Perform at Bernstein... EQT Midstream Partners (EQM) upgraded to Outperform from Neutral at Credit Suisse... Horizon Bancorp (HBNC) upgraded to Outperform from Market Perform at Raymond James... JPMorgan (JPM) upgraded to Buy from Hold at Deutsche Bank... KLA-Tencor (KLAC) upgraded to Hold from Sell at Deutsche Bank... NetEase.com (NTES) upgraded to Buy from Neutral at UBS... QLogic (QLGC) upgraded to Equal Weight from Underweight at Morgan Stanley... STMicroelectronics (STM) upgraded to Outperform from Neutral at Exane BNP Paribas... Sony (SNE) upgraded to Buy from Neutral at BofA/Merrill... Tiffany (TIF) upgraded to Overweight from Neutral at HSBC... Union First Market (UBSH) upgraded to Outperform from Neutral at RW Baird... Silicon Graphics (SGI) upgraded to Buy from Neutral at Sterne Agee... Amgen (AMGN) upgraded to Buy from Hold at Argus... CF Industries (CF) upgraded to Buy from Hold at Dahlman Rose... Agrium (AGU)upgraded to Buy from Hold at Dahlman Rose... Panera Bread (PNRA) upgraded to Buy from Hold at Miller Tabak... Halliburton (HAL) upgraded to Buy from Neutral at Global Hunter... A. Schulman (SHLM) upgraded to Buy from Hold at Gabelli.
News For AMCX;ADSK;EBAY;EQM;HBNC;JPM;KLAC;NTES;QLGC;STM;SNE;TIF;UBSH;SGI;AMGN;CF;AGU;PNRA;HAL;SHLM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 9, 2014
05:34 EDTEBAYChannelAdvisor says Amazon November SSS up 35.7%, eBay up 9.8%
Subscribe for More Information
December 8, 2014
18:19 EDTSNESony hacker releases additional private data, issues threat, Re/code says
Guardians of Peace, the hacker group claiming responsibility for the attack against Sony Pictures Entertainment, released an additional trove of private data and issued threats against the studio, according to Re/code. Reference Link
16:24 EDTAMGNAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
13:52 EDTEBAYeBay advances slightly in down tape after Stifel upgrades shares
Shares of eBay (EBAY) are rising slightly in a down market after research firm Stifel upgraded the stock to Buy from Hold. WHAT'S NEW: The risk/reward ratio on eBay appears to be favorable, Stifel analyst Scott Devitt wrote in a note to investors today. In the most likely scenario for the company, the shares could increase as high as about $65 from their current level of around $55, but are unlikely to drop much below $50, Devitt believes. In a possible bullish scenario, the shares could go up to $75, the analyst stated. The spin off of eBay's PayPal business, expected to occur within nine months, should be a significant catalyst for the stock, while the gross merchandise volume generated by the company's marketplaces business should accelerate in the second half of next year, wrote Devitt. Marketplaces comparisons become easier starting in the second half of the year, the analyst explained. Additionally, eBay will begin to emphasize that the percentage of e-commerce transactions processed by PayPal is increasing, Devitt stated. Meanwhile, eBay's valuation is "compelling," and the upcoming spin-off reminds Devitt of the separation of Expedia (EXPE) and TripAdvisor (TRIP), which proved to be a positive catalyst, he wrote. Devitt set a $65 price target on the shares. PRICE ACTION: In mid-afternoon trading, eBay gained 17c, or 0.3%, to $54.97.
10:00 EDTAMCX, KLACOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTEBAYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
09:21 EDTSNESony Pictures called the cyberattack 'unprecedented in nature', Re/code reports
Subscribe for More Information
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Amgen announced that the FDA has approved a new indication for XGEVA for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death. The approval of XGEVA is based on positive results from an open-label, single-arm study, which enrolled patients with advanced cancer and persistent hypercalcemia after recent bisphosphonate treatment. The primary endpoint was the proportion of patients with a response, defined as albumin-corrected serum calcium <11.5 mg/dLwithin 10 days after the first dose of XGEVA. Secondary endpoints included the proportion of patients who experienced a complete response (defined as CSC <10.8 mg/dL by day 10, time to response and response duration. The study achieved its primary endpoint with a response rate at day 10 of 63.6 percent in the 33 patients evaluated. The overall complete response rate was 63.6 percent. The estimated median time to response was nine days, and the median duration of response was 104 days.4,5
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Subscribe for More Information
07:31 EDTEQMEQT Corporation plans registration statement for EQT Midstream Partners
Subscribe for More Information
07:08 EDTEQMEQT Midstream Partners sees 2015 adjusted EBITDA $330M-$345M
Subscribe for More Information
07:04 EDTEQMEQT Corporation sees 2015 capital expenditures $2.5B
EQT Corporation (EQT) announced the companys 2015 capital expenditure forecast of $2.5B, excluding business development and land acquisitions. The CAPEX forecast includes $2.3B for EQT Production and $225M-$250M for EQT Midstream depending on the timing of an expected drop-down. Funding will be provided by cash generated from operations, cash-on-hand, and proceeds from midstream asset sales to EQT Midstream Partners, LP (EQM). EQTs 2015 CAPEX forecast excludes CAPEX for EQT Midstream Partners, LP, a master limited partnership controlled by EQT Corporation and consolidated in EQTs financial statements.
06:44 EDTPNRAPanera Bread coverage resumed with a Sell at Goldman
Goldman resumed coverage on Panera with a Sell rating and $139 price target. The analyst said Panera is facing significant competition from more "food forward concepts."
06:35 EDTKLACKLA-Tencor initiated with a Hold at Deutsche Bank
Subscribe for More Information
06:35 EDTJPMValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:24 EDTSNENorth Korea denies role in recent Sony hacking, WSJ reports
Subscribe for More Information
06:21 EDTJPMDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
06:17 EDTSNESony PlayStation store may have suffered possible cyberattack, AP reports
Subscribe for More Information
06:10 EDTEBAYeBay upgraded to Buy from Hold at Stifel
Subscribe for More Information
05:42 EDTAMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use